Cabaletta Bio

Q2 FY2026 EarningsQ2 FY26 results for CABA.US showed a narrower-than-expected loss, with GAAP EPS of -$0.34 beating the -$0.38 consensus. While the net loss of $51.0M was slightly wider than the $46.5M expected due to higher R&D expenses ($44.4M vs. ~$40M implied), the cash position strengthened to $225.1M following a May offering, extending the runway into mid-2027. Key operational progress remains on track, with the registrational RESET-Myositis trial targeting a 2H27 BLA submission.